Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALC
HOLDAlcon Inc. · Healthcare · Switzerland · $33.1B · Avg Vol: $140M/d
COMPANY DESCRIPTION
Alcon Inc. is the global leader in eye care, developing and manufacturing innovative surgical devices and vision care products. The company's competitive moat is sustained by its massive global distribution network, high switching costs for ophthalmic surgeons trained on its proprietary equipment, and continuous R&D investment. It operates as a highly profitable, vertically integrated player across both the surgical and contact lens markets.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 8.7B | 9.5B | 9.9B | 10.4B | 6.1% | 10.6B | 11.1B | 11.8B | 6.6% |
| EPS | — | 0.68 | 1.98 | 2.06 | 1.99 | 43.0% | 1.69 | 2.25 | 2.57 | 13.7% |
| Shares | — | 490.1M | 493.2M | 494.6M | 487.4M | -0.5% | 487.7M | — | — | — |
| Debt | — | 5.1B | 5.1B | 497.0M | 509.0M | -53.5% | 5.3B | — | — | — |
| Equity | 19.3B | 19.7B | 20.6B | 21.5B | 22.0B | 3.4% | — | — | — | — |
| Op CF | — | 1.2B | 1.4B | 2.1B | 2.3B | 23.1% | 2.3B | — | — | — |
| Inv CF | — | -1.9B | -1.1B | -1.2B | -1.3B | — | — | — | — | — |
| Fin CF | — | -8.0M | -211.0M | -322.0M | -1.1B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALC | Alcon Inc.(you) | $33.1B | 57 | HOLD |
| STMN.SW | Straumann Holding AG | $20.9B | 72 | BUY |
| YPSN.SW | YPSOMED HLDG | $5.8B | 71 | BUY |
| TECN.SW | Tecan Group AG | $2.5B | 74 | BUY |
| SDZ.SW | Sandoz Group AG | $36.5B | 62 | HOLD |
| 0K10.L | Mettler-Toledo International Inc. | $44.6B | 54 | HOLD |
| LONN.SW | Lonza Group AG | $46.1B | 49 | HOLD |
| GALD.SW | GALDERMA GROUP N | $49.5B | 66 | BUY |
| CLTN.SW | COLTENE Holding AG | $379M | 84 | STRONG BUY |
| ONC | BeOne Medicines AG | $29.0B | 74 | BUY |
Peer medians: ROE 12.1% · P/E 24.5x · Gross margin 47.5%